Clinical Trial Update: Topical CP-690,550 For Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results for topical CP-690,550 in chronic plaque psoriasis have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2020-12-31